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Abstract 
 
Background:  The American Society for Gastrointestinal Endoscopy recommends that distal 
colon hyperplastic lesions can be left in place without resection if adenomatous histology can be 
excluded with > 90% negative predictive value.  However, some of the lesions could be sessile 
serrated adenoma/polyp (SSA/P), which is also precancerous. 
 
Aim: Describe the prevalence of SSA/P in hyperplastic appearing diminutive rectosigmoid 
polyps. 
 
Methods:  We prospectively placed 513 consecutive diminutive rectosigmoid polyps that 
appeared hyperplastic to an expert endoscopist in individual bottles for pathologic examination.  
Each polyp was examined by 3 expert gastrointestinal pathologists. 
 
Results:  The prevalence of SSA/P in the study polyps ranged from 0.6% to 2.1%.  The 
endoscopists lowest negative predictive value for the combination of adenomas plus SSA/P was 
96.7% 
 
Conclusions:  The prevalence of SSA/P in diminutive rectosigmoid hyperplastic appearing polyps 
is very low.  These results support the safety and feasibility of a “do not resect” policy for 
diminutive hyperplastic appearing rectosigmoid polyps. 
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Introduction 
 
Approximately 20% to 30% of colorectal cancers arise through the serrated pathway 
1
. 
Subcategories of serrated lesions include hyperplastic polyps (HP), sessile serrated 
adenoma/polyps (SSA/P; sessile serrated polyp and sessile adenoma are synonymous terms) 
and traditional serrated adenoma (TSA) 
1
. SSA/P and TSA are considered precancerous lesions, 
whereas HP is generally considered not to be precancerous. Whether HPs are precursors of 
SSA/P remains uncertain. Because the prevalence of SSA/P is much higher than TSA, SSA/P is the 
principal serrated precancerous lesion 
2
.  
 
Endoscopic differentiation of SSA/P from HP is challenging 
2
. For example, the NICE classification 
differentiates serrated lesions from conventional adenomas, but makes no attempt to 
differentiate SSA/P from HP endoscopically 
2
. Recently, the WASP criteria have been validated 
for endoscopic differentiation of SSA/P from HP, but the success of these criteria in 
distinguishing HP from SSA/P among diminutive serrated lesions is uncertain 
3
. In general, the 
chance that a given serrated lesion is an SSA/P rather than an HP increases with lesion size and 
proximal colon location 
1, 4, 5
  
 
The issue of defining the prevalence of SSA/P within diminutive rectosigmoid polyps is assuming 
increasing importance. Anecdotally, we have observed a progressive rise in the frequency with 
which our pathologists diagnose serrated lesions SSA/P rather than HP over the past decade, 
which likely reflects ever increasing awareness of SSA/P among practicing pathologists, and this 
is well documented 6. Also anecdotally, we have observed interpretations of SSA/P in 
rectosigmoid serrated lesions. The precise prevalence of SSA/P in diminutive rectosigmoid 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
serrated lesions is of importance to both proposed and current strategies for management of 
diminutive rectosigmoid polyps at colonoscopy. For example, the American Society for 
Gastrointestinal Endoscopy (ASGE) proposed management scheme for diminutive rectosigmoid 
lesions that are deemed hyperplastic by image enhanced endoscopy, as expressed in the ASGE 
PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) document, 
recommends that such lesions can be left in place without resection if they can be predicted to 
be non-adenomatous with a greater than 90% negative predictive value (NPV) 
7
. However, the 
PIVI document does not precisely consider the prevalence of SSA/P within diminutive 
rectosigmoid serrated lesions. Arguably, the negative predictive value of image enhanced 
endoscopy should exceed 90% for conventional adenomas and SSA/P combined, since both are 
precancerous and would be expected to shorten surveillance intervals 
8
. A number of studies 
have examined the potential of image enhanced endoscopy to provide adequate NPV for 
diminutive adenomas in the rectosigmoid colon. 
4, 5, 9-14
.  In some cases these studies did not 
include SSPs with conventional adenomas in calculating NPV 
5, 12
, or did not designate precise 
numbers of SSPs vs conventional adenomas in the distal colon 
9-11
, or did not specify findings in 
the rectosigmoid 
13
 or excluded SSPs 
14
.  None of the studies used additional expert assessment 
of pathology to determine how interobserver variability in SSP interpretation would affect the 
prevalence of SSP in distal diminutive polyps. Thus, the prevalence of SSPs in diminutive 
rectosigmoid lesions that appear hyperplastic with image-enhanced endoscopy is low but not 
precisely defined.  
 
Even in the absence of a formal do not resect paradigm for the management of diminutive 
rectosigmoid serrated lesions based on image enhanced endoscopy, we considered that precise 
definition of the prevalence of SSPs in diminutive rectosigmoid hyperplastic was of importance 
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to current practice.  Thus, current endoscopic management of these lesions often involves a 
strategy of removing only a sample of these lesions. That is, when colonoscopists encounter a 
number of rectosigmoid diminutive lesions that appear endoscopically uniform and 
hyperplastic, they commonly remove only one or a few (and perhaps at times none) of these 
lesions 
15
. We suspect that in current practice, many distal hyperplastic appearing lesions are 
frequently left alone and not even mentioned in colonoscopy reports.  
 
To more precisely define the prevalence of SSA/P within diminutive rectosigmoid serrated 
lesions, we prospectively removed 513 consecutively encountered lesions that were judged by 
image enhanced endoscopy to be in the serrated class, and submitted them in individual bottles 
for pathologic assessment. Further, we had each polyp slide reviewed by an expert GI 
pathologist at our institution (JL) and 2 outside experts in serrated polyp pathology (DS and RO).  
 
Methods 
 
We prospectively undertook the study as a quality improvement project for our endoscopy unit. 
The basis for proceeding was collective agreement among our endoscopists that not all 
rectosigmoid lesions that appeared to be serrated (presumed to be hyperplastic) were being 
resected. We sought to establish the appropriateness and safety of current practice.  
 
All of the colonoscopic procedures and polyp resections were performed by a single endoscopist 
(DKR) over a 4-month interval from August 2015 to early December 2015. Patients were 
excluded if they had a known polyp syndrome (including familial adenomatous polyposis and 
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serrated polyposis), inflammatory bowel disease, or surgical resection of any portion of the 
rectosigmoid colon.  
 
All procedures were performed with high definition Olympus (Olympus Corp., Center Valley, Pa) 
190 or 180 series colonoscopes.  Polyps were usually identified in white light but always 
assessed in Narrow Band Imaging (NBI) before resection.  The NICE criteria were used to 
establish lesions as belonging to the serrated class (NICE Type 1) 
2
. 
 
We arbitrarily set the maximum number of diminutive serrated lesions that would be resected 
from an individual patient as 5 from the rectum and 5 from the sigmoid. Therefore, the total 
maximum number of endoscopically predicted diminutive serrated lesions that would be 
resected from a single patient would be 10. Before resection in patients with multiple or 
numerous diminutive serrated class appearing rectosigmoid lesions, the colonoscopist did an 
endoscopic overview of the sigmoid and rectum in an effort to select the 5 largest lesions within 
the diminutive class. No limit was placed on the number of endoscopically predicted serrated 
lesions6-9 mm in size to be resected. Each lesion was resected either with a cold snare or a cold 
forceps, as appropriate for the lesion size. In general, most lesions ≤3 mm in size were resected 
with forceps. All lesions of all sizes were resected using cold techniques. Size was determined by 
comparison to the known size of the closed forceps or snare sheath, or to the known size of the 
fully opened forceps or diminutive snare in the case of larger lesions.  
 
In order to prevent over-charging patients for pathology specimens, the pathology department 
agreed to the following scheme. Patients were charged for one bottle for all diminutive rectal 
lesions regardless of the number of bottles (which varied from 1 through 5) of diminutive rectal 
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lesions submitted. Similarly, the patient received one pathology charge for any and all sigmoid 
diminutive lesions removed, regardless of whether the number of sigmoid bottles reflecting 
diminutive polyps was 1 through 5. Similarly, for rectal lesions 6 to 9mm in size, patients 
received one pathology fee regardless of the number of lesions 6-9mm in size submitted (up to 
5) and similarly for sigmoid lesions 6 to 9 mm in size. This billing arrangement was selected to 
ensure that no patient received billing that would exceed that which would occur for the 
colonoscopist's usual practice of resecting and grouping rectosigmoid lesions that 
endoscopically appear serrated for submission to pathology.  
 
No special handling of the tissue was performed beyond placement of the tissue into its 
individual formalin bottle. That is, we did not unroll or flatten the specimens before placement 
in formalin.  
 
To derive a sample size estimate, we used pilot data as well as estimates based on our previous 
work. We estimated that the prevalence of SSA/P histology in 1 to 5 mm rectal and sigmoid 
serrated polyps could range from 2% to 12%, and set the precision of the measurement of 
prevalence at 3%. These parameters require a sample size of 451 1 to 5 mm polyps.  Assuming a 
prevalence of SSA/P of 2% to 20%, a sample size of 683 6 to 9 mm serrated polyps would be 
needed to estimate the prevalence of SSA/P in this size class of rectosigmoid polyp with a 
precision of 3%.  Only 53 lesions 6 to 9 mm in size were included, so the study had insufficient 
power to determine the prevalence of SSA/P in 6 to 9 mm rectosigmoid lesions that appear 
serrated by endoscopy.  We include the data on 6 to 9 mm polyps to inform future sample size 
estimates and illustrate pathology interpretation issues.  
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In order to obtain improved confidence regarding the study results and the appropriateness of 
our current endoscopic practice of not resecting all diminutive rectosigmoid lesions that appear 
endoscopically to be serrated, we took the following measures. First, we had all slides reviewed 
at our center by one of our expert gastrointestinal pathologists (JL-Expert 1). In addition, we 
brought in 2 outside expert pathologists (DS-Expert 2 and RO-Expert 3) to review each slide, 
each of whom is internationally recognized as an expert in serrated polyp pathology.  All 3 
experts were blinded to the readings of the original clinical pathologist and to each other’s 
readings.  The pathologists were aware that the lesions had been removed from the 
rectosigmoid and had been judged hyperplastic by the endoscopist. 
 
The pathology interpretations between pathologists were compared using kappa statistics 
16
.  
 
Results 
 
The total number of eligible colonoscopies performed during the study interval by the study 
colonoscopist was 524, of which 173 had at least one rectosigmoid lesion predicted to be 
serrated and was < 10 mm in size. The mean number of rectal and sigmoid lesions included in 
the study for those patients who had at least one lesion included is shown in Table 1. Again, the 
maximum number of diminutive lesions in the rectum included from an individual patient was 5, 
and similarly it was 5 for the sigmoid, so that the maximum number of diminutive rectosigmoid 
lesions appearing endoscopically to be serrated to be removed was 10. The number of patients 
with 10 lesions included in the study was 9. No patient had 10 lesions 6 to 9 mm in size included. 
Overall, 90.6% of included lesions were ≤ 5 mm in size, and 513 lesions ≤ 5 mm in size were 
included, and 53 6 to 9 mm in size.  
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Table 2 shows the interpretations of the lesions by size and according to the interpretation of 
the 3 expert gastrointestinal pathologists. Considering all 3 sets of interpretations for the 
diminutive lesions, the study colonoscopist's endoscopic predictions had a lowest negative 
predictive value for conventional adenomas of 98.2% (95% CI, 96.7% - 99.2%)(see pathologist 
Expert 3; Table 2), a lowest negative predictive value for sessile serrated polyp of 97.9% (95% CI, 
96.2% - 98.9%)(see pathologist Expert 1; Table 2) and a lowest negative predictive value for 
conventional adenoma plus SSA/Ps of 96.7% (95% CI, 94.8% - 98.1%)(see pathologist Expert 1; 
Table 2).  
 
 
Table 3 shows pairwise kappa values for the interpretation of lesions between the 3 expert 
pathologists, and according to lesion size. Agreement between the 2 outside experts was 
substantial, while agreement between the IU expert and the 2 outside experts was fair to 
moderate. Table 2 shows that these differences manifest largely in a greater tendency to 
interpret SSA/P by the IU pathologist compared to the 2 outside experts. A clinical impact of this 
difference seems minimal for diminutive rectosigmoid lesions, since the absolute level of 
predicting SSA/P in this size group was very low for all 3 pathologists. A clinical impact is 
potentially larger for 6 to 9 mm lesions. Although the total number of lesions in that size range is 
small, and the prevalence of SSA/P estimated by the 3 pathologists lacks precision, the absolute 
frequency of SSA/P in 6 to 9 mm polyps was 11.3% for the IU expert pathologist, which 
exceeded the absolute prevalence of SSA/P in 6 to 9 mm lesions interpreted by the 2 outside 
experts. 
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For pathology expert 1, the 17 SSA/Ps came from 13 different patients.  For pathology experts 2 
and 3 (Table 2), each SSA/P identified came from a different patient.   
 
Discussion 
 
In this prospective study we demonstrated that the prevalence of SSA/P is very low in 
diminutive endoscopic lesions predicted endoscopically to be serrated by an expert endoscopist. 
The absolute level of SSA/P in diminutive rectosigmoid lesions ranged from 0.6% to 2.1% as 
interpreted by 3 expert gastrointestinal pathologists. The small number of SSA/Ps identified had 
minimal tendency  to cluster within individual patients.  We believe these results support the 
current colonoscopic practice of our endoscopists, which is to not resect all diminutive 
endoscopically serrated appearing (hyperplastic appearing) rectosigmoid polyps. We believe this 
conclusion is reinforced by the limited certainty regarding appropriate pathologic definitions of 
SSA/P versus HP, and the unknown clinical importance of diminutive SSA/Ps anywhere in the 
colon. We caution, however, that endoscopic criteria for differentiation of SSA/P from HP are 
emerging, and endoscopists could still be reasonably advised to resect and submit to pathology 
any lesion with endoscopic features found in the WASP classification that predict SSA/P 
histology, even when the lesion is diminutive and located in the rectosigmoid. In our experience, 
this consideration mainly applies to serrated  lesions with large open pits because other WASP 
criteria such as indiscrete edges, a cloud-like appearance, and an irregular surface 
3
, are seldom 
observed in diminutive lesions that appear otherwise to be serrated class (NICE type I lesions).  
 
Our data are also reassuring with regard to the PIVI policy that proposes management of 
diminutive rectosigmoid lesions by a “do not resect” approach. First we confirm that the 
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negative predictive value of an expert endoscopist for interpretation of conventional adenomas 
far exceeds the recommended PIVI threshold of 90%
7
. Further, the 90% negative predictive 
value threshold is exceeded for the combination of conventional adenoma and SSA/P. Our 
sample size is sufficient to establish that the lower confidence limit for our estimate of the 
prevalence of TA an SSA/P combined is such that the negative predictive value still substantially 
exceeds 90%.  
 
Other studies have reported that academic and community endoscopist can meet the PIVI 
threshold of at least 90% NPV for adenomas in diminutive rectosigmoid lesions 
5, 9-14
, including 
when SSPs were counted as adenomas 
9-11, 13
.  We found that absolute prevalence of SSPs in 
diminutive rectosigmoid lesions that appear hyperplastic was 0.6% to 2.1% according to 
pathology interpretations by three expert pathologists.  Our results are similar to but 
numerically slightly higher than 0.5% prevalence of SSP determined by a single expert Japanese 
pathologist in diminutive rectosigmoid lesions that appeared endoscopically hyperplastic 
4
.  
 
We observed a very good agreement between 2 outside expert pathologists in the 
interpretation of diminutive rectosigmoid lesions that were endoscopically predicted to be 
serrated lesions. This excellent agreement between the 2 outside expert pathologists extended 
to the small number of lesions 6 to 9 mm in size. Agreement between our expert pathologist 
and the 2 outside experts was only moderate. In general, our expert tended to call more SSA/Ps 
than the outside experts, and although our estimates lacked precision for 6-9 mm lesions 
because of limited sample size, the absolute level of SSA/P interpretation was of potential 
clinical significance for our pathologist. Our data indicate that to some extent interpretation of 
SSA/P is occasionally challenging even for expert pathologists. 
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 Some recent work found that some pathologists were never diagnosing SSA/P in serrated 
lesions as late as a few years ago 
17
. Further, substantial data suggest that polyps read as HP a 
decade or more ago are commonly currently interpreted by experts as SSA/P 
18
.  We observed 
this in our own program nearly a decade ago 
19
. Individual endoscopists in either community or 
academic settings are unlikely to have a sense of the frequency with which their own 
pathologists interpret precancerous serrated lesions (SSA/P without or with cytological dysplasia 
and TSA) unless they measure these frequencies and compare them to published frequencies by 
pathology experts. Unfortunately, there is enough variation between expert pathologists in 
interpretation of SSA/P, that establishing standards for the expected prevalence of SSA/P in 
serrated lesions of different sizes, and from different portions of the colon, would be hard to 
establish. Fortunately, our data show that the prevalence of SSA/P in diminutive rectosigmoid 
serrated lesions is very low across 3 expert pathologists, supporting current practice of not 
systematically resecting all diminutive serrated appearing lesions in the rectosigmoid during 
colonoscopy. Our data also support that, while the prevalence of SSA/P in 6 to 9 mm serrated 
appearing lesions is low, such lesions should likely be resected and submitted to pathology. Such 
a policy is certainly consistent with the PIVI proposed paradigm, which suggests that "do not 
resect" be applied only to diminutive rectosigmoid lesions that appear serrated. Finally, our data 
suggest that more sophisticated or advanced endoscopic quality programs might survey the 
prevalence of SSA/P in diminutive rectosigmoid serrated appearing lesions in their own 
institutions, to establish whether the observed prevalence is consistent with the very low 
prevalences of SSA/P observed in this study. Higher rates of SSA/P in individual programs might 
warrant review of histologic criteria for SSA/P by individual pathologists or consultation with an 
outside expert pathologist.  
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Limitations of the study include the small number of experts who evaluated the slides.  Further, 
the experts were aware that the polyps were removed from the rectosigmoid, and that they 
were considered serrated lesions by the endoscopist.  The latter awareness might have biased 
the interpretations of the endoscopists.  However, in clinical practice pathologists are also 
generally aware of colon segments from which polyps were removed.  Also, the kappa values 
between the outside expert pathologists showed substantial interobserver agreement, 
suggesting that any bias had very limited impact in the differentiation of HP from SSA/P.   
 
In summary, we established in a prospective study designed to verify the safety of our current 
endoscopic practice, that the prevalence of SSA/P in rectosigmoid diminutive lesions judged to 
be in the serrated class by an expert endoscopist is very low. These results support current 
colonoscopic practice of not systematically removing all diminutive rectosigmoid lesions that 
appear serrated (hyperplastic) and support the "do not resect" paradigm proposed by the ASGE 
PIVI on management of diminutive colorectal polyps 
7
.  
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Table 1:  Mean numbers of serrated lesions by location and size in 173 patients with at 
least one study polyp 
 
Lesion 
size 
Number of patients 
with ≥ 1 polyp 
Number of patients 
with only 1 lesion 
Mean number of study 
lesions per patient with ≥ 1 
lesion 
Number of 
patients with 
10 lesions 
≤ 5 mm 159 56 3.22 9 
6-9 mm 22 10 1.31 0 
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Table 2: Polyp histology according to size by three expert pathologists in 566 polyps 
deemed to be serrated endoscopically by a single expert endoscopist.   
Polyp Size Reviewer 
Polyp Histology 
HP SSA/P TSA TA Mucosa 
≤ 5mm 
Expert 1 436 (85.0%) 11 (2.1%) 0 (0%) 6 (1.2%) 60 (11.7%) 
Expert 2 449 (87.5%) 3 (0.6%) 0 (0%) 8 (1.6%) 53 (10.3%) 
Expert 3 451 (87.9%) 7 (1.4%) 0 (0%) 9 (1.8%) 46 (9.0%) 
6-9 mm 
Expert 1 43 (81.1%) 6 (11.3%) 0 (0%) 2 (3.8%) 2 (3.8%) 
Expert 2 48 (90.6%) 1 (1.9%) 1 (1.9%) 2 (3.8%) 1 (1.9%) 
Expert 3 49 (92.5%) 1 (1.9%) 0 (0%) 2 (3.8%) 1 (1.9%) 
 
HP: hyperplastic polyp; SSA/P: sessile serrated adenoma/polyp; TSA: traditional serrated 
adenoma; TA: tubular adenoma; Mucosa: no histological evidence of polyp 
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Table 3: Pairwise kappa value comparison between expert pathologists 
 
Comparison 
Kappa values (95% CI) 
≤ 5mm 6-9mm 
Expert 1 vs Expert 2 0.58 (0.48-0.69) 0.42 (0.12-0.72) 
Expert 1 vs Expert 3 0.59 (0.49-0.69) 0.39 (0.05-0.72) 
Expert 2 vs Expert 3 0.74 (0.66-0.83) 0.77 (0.49-1.00) 
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SSA/P: sessile serrated adenoma/polyp 
HP: hyperplastic polyps 
TSA: traditional serrated adenoma 
NICE: Narrow band imaging International Colorectal Endoscopic Classification 
WASP: Workgroup serrated polypS & Polyposis 
ASGE: American Society for Gastrointestinal Endoscopy 
PIVI: Preservation and Incorporation of Valuable Endoscopic Innovations 
GI: gastrointestinal  
JL: Jingmei LIn 
DS: Dale Snover 
RO: Robert Odze 
DKR: Douglas Kevin Rex 
mm: Millimeters 
IU: Indiana University 
TA: tubular adenoma 
 
 
